Vertex Pharmaceuticals (VRTX) gains on FDA nod

Vertex Pharmaceuticals Incorporated

shares gained 4% to $129.02, on news that a regulatory advisory committee recommended approval of its cystic fibrosis treatment called Orkambi. An FDA decision is expected by July 5. Share volume came in at two million, eclipsing an all-day average of 1.6 million